The Hartford $345 Million Depositary Shares Offering
Davis Polk advised the representatives of the several underwriters on the offering by The Hartford Financial Services Group, Inc. of $345 million of depositary shares, each…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Heineken strategic partnership with China Resources to join forces in China
Davis Polk is advising Heineken N.V. in connection with its entry into definitive agreements with China Resources Enterprise (“CRE”) and China Resources Beer (Holdings) Co. Ltd. (“CR Beer”)…
Orchard Therapeutics plc Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $225 million initial public offering by Orchard Therapeutics…
Davis Polk Advises Commonwealth Bank of Australia on the Sale of Its Asset Management Business to Mitsubishi UFJ Trust and Banking Corporation
Davis Polk is advising Commonwealth Bank of Australia on the U.S. aspects of its $4.1 billion sale of the Colonial First State Global Asset Management business to Mitsubishi UFJ Trust and…
Encana Acquires Newfield Exploration Company
Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to Newfield Exploration Company in connection with its approximately $5.5 billion acquisition by Encana…
Province of Alberta $2.25 Billion SEC-Registered Global Bond Offering
Davis Polk advised the underwriters in connection with the offering of $2.25 billion aggregate principal amount of 3.350% bonds due November 1, 2023, issued by the Province of Alberta. …
Sinopec Group Medium-Term Note Program Update and HK$1.2 Billion and RMB1 Billion Notes Drawdown
Davis Polk advised the dealers in connection with the update of the $3 billion medium-term notes program by Sinopec Century Bright Capital Investment Limited, guaranteed by China…
Davis Polk Advises Novo Nordisk on Its Acquisition of U.S. and Canadian Rights to Macrilen from Strongbridge Biopharma
Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…
Innovent Biologics, Inc. HK$3.15 Billion (US$403.1 Million) Initial Public Offering
Davis Polk advised the underwriters and joint global coordinators in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on…
Oceanwide Holdings International Development III Co., Ltd. $215 Million Notes Offering
Davis Polk advised the initial purchasers in connection with a $215 million Regulation S only offering by Oceanwide Holdings International Development III Co., Ltd of its 12.00%…